JP2010539950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539950A5 JP2010539950A5 JP2010527254A JP2010527254A JP2010539950A5 JP 2010539950 A5 JP2010539950 A5 JP 2010539950A5 JP 2010527254 A JP2010527254 A JP 2010527254A JP 2010527254 A JP2010527254 A JP 2010527254A JP 2010539950 A5 JP2010539950 A5 JP 2010539950A5
- Authority
- JP
- Japan
- Prior art keywords
- exon
- item
- compound
- intron
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 124
- 108091034117 Oligonucleotide Proteins 0.000 claims description 91
- 239000002777 nucleoside Substances 0.000 claims description 66
- 125000003835 nucleoside group Chemical group 0.000 claims description 46
- 230000000295 complement effect Effects 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 25
- 208000008589 Obesity Diseases 0.000 claims description 19
- 239000003472 antidiabetic agent Substances 0.000 claims description 19
- 229940126904 hypoglycaemic agent Drugs 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 19
- 235000020824 obesity Nutrition 0.000 claims description 19
- 239000000883 anti-obesity agent Substances 0.000 claims description 17
- 229940125710 antiobesity agent Drugs 0.000 claims description 17
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 15
- 210000001789 adipocyte Anatomy 0.000 claims description 14
- 210000000577 adipose tissue Anatomy 0.000 claims description 14
- 206010022489 Insulin Resistance Diseases 0.000 claims description 13
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 13
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 13
- 238000007911 parenteral administration Methods 0.000 claims description 12
- 239000000164 antipsychotic agent Substances 0.000 claims description 11
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims description 10
- 102000055699 human FGFR4 Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 230000037323 metabolic rate Effects 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000003337 fertilizer Substances 0.000 claims 1
- -1 thio benzoate nucleoside Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 75
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 108020005345 3' Untranslated Regions Proteins 0.000 description 20
- 108091081024 Start codon Proteins 0.000 description 20
- 108020003589 5' Untranslated Regions Proteins 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000001934 delay Effects 0.000 description 5
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97678207P | 2007-10-01 | 2007-10-01 | |
| US60/976,782 | 2007-10-01 | ||
| PCT/US2008/078497 WO2009046141A2 (en) | 2007-10-01 | 2008-10-01 | Antisense modulation of fibroblast growth factor receptor 4 expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539950A JP2010539950A (ja) | 2010-12-24 |
| JP2010539950A5 true JP2010539950A5 (enExample) | 2011-11-24 |
| JP5792955B2 JP5792955B2 (ja) | 2015-10-14 |
Family
ID=40526946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527254A Expired - Fee Related JP5792955B2 (ja) | 2007-10-01 | 2008-10-01 | 線維芽細胞増殖因子受容体４発現のアンチセンスモジュレーション |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8486904B2 (enExample) |
| EP (1) | EP2215102B1 (enExample) |
| JP (1) | JP5792955B2 (enExample) |
| KR (1) | KR101660989B1 (enExample) |
| CN (1) | CN101883777B (enExample) |
| AU (1) | AU2008308691B2 (enExample) |
| BR (1) | BRPI0817527A2 (enExample) |
| CA (1) | CA2701128A1 (enExample) |
| IL (1) | IL204796A (enExample) |
| MX (1) | MX2010003606A (enExample) |
| NZ (1) | NZ584827A (enExample) |
| RU (1) | RU2501803C2 (enExample) |
| WO (1) | WO2009046141A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009046141A2 (en) | 2007-10-01 | 2009-04-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| EP2419146A4 (en) * | 2009-04-15 | 2013-11-27 | Isis Pharmaceuticals Inc | MODULATION OF IGNITION REACTIONS BY FACTOR XI |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| JP5951752B2 (ja) | 2011-04-13 | 2016-07-13 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｐｔｐ１ｂ発現のアンチセンス調節 |
| CA2839437A1 (en) * | 2011-06-16 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN102337247B (zh) * | 2011-09-13 | 2013-07-10 | 西安交通大学 | 一种fgfr4高表达的重组hek293细胞及其应用 |
| PE20190736A1 (es) | 2012-06-13 | 2019-05-23 | Incyte Holdings Corp | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9175291B2 (en) * | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| SG11201503821YA (en) | 2012-11-15 | 2015-06-29 | Roche Innovation Ct Copenhagen As | Oligonucleotide conjugates |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| RU2649367C2 (ru) | 2013-01-30 | 2018-04-02 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты углевода и lna-олигонуклеотида |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| KR102482890B1 (ko) | 2013-05-01 | 2022-12-30 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법 |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
| WO2015143246A1 (en) | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Compositions for modulating ataxin 2 expression |
| CN110903337A (zh) | 2014-05-01 | 2020-03-24 | Ionis制药公司 | 用于调节生长激素受体表达的组合物和方法 |
| WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2895769T3 (es) | 2015-02-20 | 2022-02-22 | Incyte Corp | Heterociclos bicíclicos como inhibidores de FGFR |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| PE20180800A1 (es) * | 2015-07-10 | 2018-05-09 | Ionis Pharmaceuticals Inc | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) |
| EP3397288A4 (en) | 2015-12-31 | 2019-09-11 | Ionis Pharmaceuticals, Inc. | PROCESS FOR REDUCING ATAXIN-2 EXPRESSION |
| CN109661233A (zh) | 2016-10-06 | 2019-04-19 | Ionis 制药公司 | 缀合低聚化合物的方法 |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| SI3788047T1 (sl) | 2018-05-04 | 2024-11-29 | Incyte Corporation | Trdne oblike inhibitorja fgfr in postopki priprave le-teh |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| MX2021000922A (es) | 2018-07-25 | 2021-03-31 | Ionis Pharmaceuticals Inc | Compuestos y metodos para reducir la expresion de la atxn2. |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN112759593A (zh) | 2019-11-01 | 2021-05-07 | 北京伯汇生物技术有限公司 | 桥环并醛基吡啶衍生物及其应用 |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0420081A1 (en) | 1989-09-26 | 1991-04-03 | Takeda Chemical Industries, Ltd. | Monoclonal antibody against an acidic FGF protein, its production and use |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US20040006005A1 (en) * | 2002-07-02 | 2004-01-08 | Sanjay Bhanot | Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes |
| CA2152903A1 (en) * | 1992-12-31 | 1994-07-21 | Larry A. Denner | Antisense molecules directed against a fibroblast growth factor receptor gene family |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US20050053976A1 (en) * | 1996-06-06 | 2005-03-10 | Baker Brenda F. | Chimeric oligomeric compounds and their use in gene modulation |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| ATE212552T1 (de) | 1998-04-17 | 2002-02-15 | Tufts College | Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten |
| US6821724B1 (en) * | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
| US6153432A (en) | 1999-01-29 | 2000-11-28 | Zen-Bio, Inc | Methods for the differentiation of human preadipocytes into adipocytes |
| US6136603A (en) * | 1999-03-26 | 2000-10-24 | Isis Pharmaceuticals Inc. | Antisense modulation of interleukin-5 signal transduction |
| WO2000071129A1 (en) | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| DE60028054T2 (de) | 1999-09-08 | 2006-12-21 | Genentech, Inc., South San Francisco | Fibroblasten-wachstumsfaktor-19 (fgf-19) nukleinsäure und polypeptide und verfahren zu deren verwendung für behandlung von fettleibigkeit |
| AU2631001A (en) | 2000-01-05 | 2001-07-16 | Zymogenetics Inc. | Novel fgf homolog zfgf11 |
| US6261840B1 (en) * | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US6159734A (en) * | 2000-01-18 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of peroxisome proliferator-activated receptor gamma expression |
| CA2403572A1 (en) | 2000-03-22 | 2001-09-27 | Amgen Inc. | Fibroblast growth factor receptor-like molecules and uses thereof |
| US20020001825A1 (en) | 2000-03-31 | 2002-01-03 | Nobuyuki Itoh | Fibroblast growth factor-like molecules and uses thereof |
| US20030212024A1 (en) | 2000-05-12 | 2003-11-13 | Keating Mark T | Compositions and methods for cell dedifferentiation and tissue regeneration |
| EP1202065A1 (en) | 2000-10-25 | 2002-05-02 | Aventis Pharma S.A. | Net, a transcription factor of the TCF family, as regulator of angiogenic expression. |
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| DE10152147A1 (de) | 2001-10-25 | 2003-05-15 | Chemogenix Gmbh | Verfahren zum Aufbringen von Nukleosiden und/oder Nukleotiden auf funktionalisierten Oberflächen sowie Verfahren zur Bestimmung von Kopplungsausbeuten bei der Synthese von Nukleotiden |
| IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| US7655397B2 (en) * | 2002-04-25 | 2010-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers |
| US7122550B2 (en) | 2002-05-23 | 2006-10-17 | Cytopia Pty Ltd | Protein kinase inhibitors |
| TW200401638A (en) | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
| AU2003236557B2 (en) * | 2002-06-27 | 2009-10-01 | Verva Pharmaceuticals Pty Ltd | Differentiation modulating agents and uses therefor |
| CN100565305C (zh) | 2002-07-08 | 2009-12-02 | 皇家飞利浦电子股份有限公司 | 反射型立体显示器 |
| JP2006513159A (ja) | 2002-11-01 | 2006-04-20 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体 |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US7803781B2 (en) * | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| US20050048494A1 (en) | 2003-08-28 | 2005-03-03 | Yixin Wang | Colorectal cancer prognostics |
| CA2762955A1 (en) * | 2003-10-16 | 2005-04-28 | Imclone Llc | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| CA2550245A1 (en) * | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| CN101044152A (zh) * | 2004-02-05 | 2007-09-26 | 因特拉迪格姆公司 | 组合RNAi治疗的方法和组合物 |
| US20090247604A1 (en) * | 2004-02-05 | 2009-10-01 | Intradigm Corporation | RNAi Therapeutics for Treatment of Eye Neovascularization Diseases |
| US7374927B2 (en) * | 2004-05-03 | 2008-05-20 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
| US20060286102A1 (en) * | 2004-05-14 | 2006-12-21 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
| EP1807093A2 (en) * | 2004-10-13 | 2007-07-18 | Isis Pharmaceuticals, Inc. | Antisense modulation of ptp1b expression |
| EP1954708A4 (en) * | 2005-11-23 | 2009-05-13 | Univ Utah Res Found | Methods and compositions involving intrinsic genes |
| EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| WO2008109369A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| US20100105134A1 (en) * | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| WO2009046141A2 (en) | 2007-10-01 | 2009-04-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
-
2008
- 2008-10-01 WO PCT/US2008/078497 patent/WO2009046141A2/en not_active Ceased
- 2008-10-01 MX MX2010003606A patent/MX2010003606A/es active IP Right Grant
- 2008-10-01 EP EP08835484.0A patent/EP2215102B1/en not_active Not-in-force
- 2008-10-01 RU RU2010116994/10A patent/RU2501803C2/ru not_active IP Right Cessation
- 2008-10-01 KR KR1020107009236A patent/KR101660989B1/ko not_active Expired - Fee Related
- 2008-10-01 BR BRPI0817527A patent/BRPI0817527A2/pt not_active IP Right Cessation
- 2008-10-01 CN CN200880118757.3A patent/CN101883777B/zh not_active Expired - Fee Related
- 2008-10-01 CA CA2701128A patent/CA2701128A1/en not_active Abandoned
- 2008-10-01 JP JP2010527254A patent/JP5792955B2/ja not_active Expired - Fee Related
- 2008-10-01 NZ NZ584827A patent/NZ584827A/xx not_active IP Right Cessation
- 2008-10-01 US US12/681,360 patent/US8486904B2/en not_active Expired - Fee Related
- 2008-10-01 AU AU2008308691A patent/AU2008308691B2/en not_active Ceased
-
2010
- 2010-03-28 IL IL204796A patent/IL204796A/en not_active IP Right Cessation
-
2013
- 2013-06-12 US US13/915,855 patent/US8895529B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539950A5 (enExample) | ||
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| JP2012050438A5 (enExample) | ||
| JP2012050439A5 (enExample) | ||
| US10329567B2 (en) | Chimeric double-stranded nucleic acid | |
| EP3325097B1 (en) | Compositions and agents against hepatitis b virus and uses thereof | |
| US11534452B2 (en) | Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection | |
| JP2009508527A5 (enExample) | ||
| JP2016530882A5 (enExample) | ||
| JP2024056842A5 (enExample) | ||
| JP2012508560A5 (enExample) | ||
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2016502858A5 (enExample) | ||
| JP2018184423A5 (enExample) | ||
| AU2018208505A1 (en) | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | |
| JP2003523739A5 (enExample) | ||
| JP2016522817A5 (enExample) | ||
| JP7095893B2 (ja) | アンチセンスオリゴ核酸 | |
| TW201825101A (zh) | 寡聚物及寡聚物結合物 | |
| EP2101789B1 (en) | Combined telomerase inhibitor and gemcitabine for the treatment of cancer | |
| JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
| JP2007505627A5 (enExample) | ||
| JP2016523548A5 (enExample) | ||
| JP2024037841A5 (enExample) | ||
| TW202113079A (zh) | 經修飾之間隙子寡核苷酸及其使用方法 |